Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN046 + carboplatin + pemetrexed
- Development stage
- Discontinued
- Lead developer
- AlphaMab Oncology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
KN046 + carboplatin + pemetrexed is a combination therapy consisting of a bispecific antibody targeting PD-L1 and CTLA-4 (KN046) with two chemotherapy agents (carboplatin and pemetrexed). This regimen is being investigated for the treatment of metastatic non-small cell lung cancer (NSCLC). KN046 is a novel bispecific antibody that simultaneously blocks PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86, potentially offering synergistic antitumor effects. The addition of carboplatin and pemetrexed chemotherapy to this immunotherapy approach aims to enhance treatment efficacy. Clinical trials have shown promising results with manageable side effects.
02
Targets
ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)
Beyond the preview
Go deeper on KN046 + carboplatin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN046 + carboplatin + pemetrexed.